|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 750 9th Street, NW |
Address2 | Suite 575 |
City | Washington |
State | DC |
Zip Code | 20001-4584 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 57954-12
|
||||||||
|
6. House ID# 352640002
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Andrew Kaplan |
Date | 4/22/2024 3:06:33 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues
Policies to enhance patient access to medicines in Medicare
CMS Medicaid Drug Rebate Proposed Rule - issues related to best price and survey
Medicare Prescription Drug Inflation Rebate Program Part B Rebatable Drug Coinsurance Reduction Drug List
Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026
Discussions on biosimilars related to IRA
Discussions on spillover related to the IRA
P.L. 117-169 Inflation Reduction Act - reconciliation package with provisions related to prescription drug prices, implementation, negotiation, Part D redesign, inflation penalties
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelley |
Stewart |
|
|
|
Andrew |
Kaplan |
|
|
|
Kirsten |
Powell |
|
|
|
Natalie |
Morris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Clarify or reform the 340B program
Patient access of plasma therapies
Global pharmaceutical supply chain operations and manufacturing locations
Most Favored Nation/International Reference Pricing
Co-pay accumulators maximizers, alternate funding models
Promoting the Congressional Plasma Caucus
Senate Finance Committee PBM Framework Paper
Pharmacy Benefit Managers (PBMs)
S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy
H.R. 2534, PROTECT 340B Act of 2023
S. 2333, Pandemic and All-Hazards Preparedness and Response Act
H.R. 830, S.1375, HELP Co-Pays Act
H.R. 5539, S. 3131, ORPHAN Cures Act
H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to transparency and data disclosure for PBMs
H.R. 2816, The PBM Sunshine and Accountability Act
H.R. 2880, Protecting Patients Against PBM Abuses Act
S. 127, Pharmacy Benefit Manager Transparency Act
S.1131, Drug Price Transparency Act of 2023
S.1339, Pharmacy Benefit Manager Reform Act
S. 4293, Pharmacy Benefit Manager Transparency Act of 2022
H.R. 5378, The Lower Costs, More Transparency Act
S. 2973, Modernizing and Ensuring PBM Accountability Act
Issues related to dengue vaccines
H.R. 6283, S. 1542, Delinking Revenue from Unfair Gouging "DRUG Act"
S.1264, Strengthening Medicare And Reducing Taxpayer (SMART) Prices Ac
H.R. 7174, Ensuring Pathways to Innovative Cures (EPIC) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelley |
Stewart |
|
|
|
Andrew |
Kaplan |
|
|
|
Kirsten |
Powell |
|
|
|
Natalie |
Morris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 866/H.R. 2673, A bill to amend the Internal Revenue Code of 1986 to enhance tax benefits for research activities - issues related to R&D amortization
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelley |
Stewart |
|
|
|
Kirsten |
Powell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues related to trade-related pharmaceutical intellectual property (TRIPS)
General intellectual property policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kirsten |
Powell |
|
|
|
Andrew |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY2024, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations
H.R. 2882, P.L. 118-47, Further Consolidated Appropriations Act 2024
H.R. 4366, P.L. 118-42 Consolidated Appropriations Act 2024
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelley |
Stewart |
|
|
|
Kirsten |
Powell |
|
|
|
Natalie |
Morris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R. 7085, BIOSECURE ACT
S. 3385, A bill to prohibit contracting with certain biotechnology providers
S. 3558, A bill to prohibit contracting with certain biotechnology providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kirsten |
Powell |
|
|
|
Andrew |
Kaplan |
|
|
|
Natalie |
Morris |
|
|
|
Shelley |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |